{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:36:35Z","timestamp":1790984195367,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Guselkumab is proven effective and safe for moderate-to-severe plaque psoriasis, but its safety in patients with comorbid infectious diseases and malignancies has been less studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The EARLY study was a real-world longitudinal study designed to assess clinical outcomes and long-term safety of guselkumab in patients with psoriasis who also had chronic infections, malignancies or heart disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cohort of 1024 patients with moderate-to-severe psoriasis treated with guselkumab was evaluated for the presence of chronic infection [hepatitis B virus (HBV) and hepatitis C virus (HCV), tuberculosis and HIV] and cancer. Subgroup analysis was also performed in patients with heart disease. Patients with cancer were categorized into the precedent cancer (PC) group, with diagnoses made before the study, and the intercurrent cancer (IC) group, with diagnosis occurring during the study. Stratification was also performed based on oncological risk (high-risk and low-risk groups), according to 2022 Italian guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1024 patients, 7.5% (n = 77) had HBV, 7.4% (n = 76) had latent tuberculosis infection, 2.7% (n = 28) had HCV, and 0.8% (n = 8) were HIV-positive. In these patients (n = 189), no reactivation of infectious diseases was observed during a mean follow-up period of 128.5 (SD 81.2) weeks. In the 65 patients with cancer (6.3% of the cohort), 78% (n = 51) were in the PC group and 22% (n = 14) were in the IC group. Time from cancer diagnosis to guselkumab initiation averaged 11.8 (SD 15.5) months in patients at high risk and 113.3 (SD 58.5) months in patients at low risk. In patients with heart disease, mean follow-up was 121.0 (SD 76.9) weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This longitudinal real-world study demonstrates the long-term safety of guselkumab in patients with psoriasis who had chronic infections, cancer or heart disease. Stratification by oncological risk provided valuable insights for therapeutic management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf172","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:25:39Z","timestamp":1744701939000},"page":"1786-1794","source":"Crossref","is-referenced-by-count":8,"title":["A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study"],"prefix":"10.1093","volume":"50","author":[{"given":"Edoardo","family":"Mortato","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]},{"name":"Department of Dermatology, University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione Policlinico \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Marcelli","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Raimondo","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u2018Scuola Medica Salernitana\u2019, University of Salerno , Salerno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9232","authenticated-orcid":false,"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3574","authenticated-orcid":false,"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u2018Daniele Innocenzi\u2019, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania Luigi Vanvitelli , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences \u2013 Dermatological Clinic, Universit\u00e0 Politecnica delle Marche , Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-6993","authenticated-orcid":false,"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bonifati","sequence":"additional","affiliation":[{"name":"Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Lora","sequence":"additional","affiliation":[{"name":"Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[{"name":"Department of Medicine Surgery and Dentistry, \u2018Scuola Medica Salernitana\u2019, University of Salerno , Salerno ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Luca","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u2018Daniele Innocenzi\u2019, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Buononato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania Luigi Vanvitelli , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS INRCA , Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[{"name":"San Gallicano Dermatological Institute, IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7997-1784","authenticated-orcid":false,"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Primavera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Bari , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]},{"name":"Dermatology Unit, Fondazione Policlinico \u2018Tor Vergata\u2019 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2025082212470808200_llaf172-B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.31138\/mjr.040123.sot","article-title":"State of the art review on the treatment of psoriatic disease","volume":"35","author":"Pelechas","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"2025082212470808200_llaf172-B2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J Dermatol"},{"key":"2025082212470808200_llaf172-B3","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3390\/biomedicines9101482","article-title":"New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge?","volume":"9","author":"Megna","year":"2021","journal-title":"Biomedicines"},{"key":"2025082212470808200_llaf172-B4","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082212470808200_llaf172-B5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470808200_llaf172-B6","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"2025082212470808200_llaf172-B7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025082212470808200_llaf172-B8","doi-asserted-by":"crossref","first-page":"e14584","DOI":"10.1111\/dth.14584","article-title":"Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience","volume":"34","author":"Bonifati","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025082212470808200_llaf172-B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjd.12120","article-title":"Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient","volume":"168","author":"Koskinas","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025082212470808200_llaf172-B10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2024.01.039","article-title":"Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: a multicenter prospective cohort study","volume":"90","author":"Huang","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470808200_llaf172-B11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"2025082212470808200_llaf172-B12","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"2025082212470808200_llaf172-B13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470808200_llaf172-B14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol"},{"key":"2025082212470808200_llaf172-B15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00011-017-1065-z","article-title":"\u201cInflammatory skin march\u201d in atopic dermatitis and psoriasis","volume":"66","author":"Furue","year":"2017","journal-title":"Inflamm Res"},{"key":"2025082212470808200_llaf172-B16","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2025082212470808200_llaf172-B17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025082212470808200_llaf172-B18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025082212470808200_llaf172-B19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumour necrosis factor-\u03b1 inhibitors versus methotrexate","volume":"76","author":"Wu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470808200_llaf172-B20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470808200_llaf172-B21","doi-asserted-by":"crossref","first-page":"2241585","DOI":"10.1080\/09546634.2023.2241585","article-title":"Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study","volume":"34","author":"Ibba","year":"2023","journal-title":"J Dermatol Treat"},{"key":"2025082212470808200_llaf172-B22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","article-title":"Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults","volume":"17","author":"Boehncke","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2025082212470808200_llaf172-B23","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1111\/jdv.20341","article-title":"Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: a multicentric real-world study","volume":"39","author":"Raimondo","year":"2025","journal-title":"Acad Dermatol Venereol"},{"key":"2025082212470808200_llaf172-B24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s13555-022-00726-w","article-title":"Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025082212470808200_llaf172-B25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2025082212470808200_llaf172-B26","doi-asserted-by":"crossref","first-page":"e1203","DOI":"10.1111\/jdv.19186","article-title":"Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: a multicentric retrospective cohort study of 49 patients","volume":"37","author":"Ciolfi","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470808200_llaf172-B27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CCID.S403294","article-title":"Efficacy and safety of tildrakizumab in a patient with chronic HBV infection","volume":"16","author":"Potestio","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025082212470808200_llaf172-B28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/bjd\/ljad081","article-title":"Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","volume":"189","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025082212470808200_llaf172-B29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470808200_llaf172-B30","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/annrheumdis-2022-eular.849","article-title":"AB0882 Guselkumab: description of cardiovascular risk and efficacy in psoriasis and psoriatic arthritis in real clinical practice","volume":"81","author":"Gilabert","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025082212470808200_llaf172-B31","doi-asserted-by":"crossref","first-page":"2331807","DOI":"10.1080\/09546634.2024.2331807","article-title":"Successful treatment of generalized pustular psoriasis with guselkumab","volume":"35","author":"Part","year":"2024","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl. 3","key":"2025082212470808200_llaf172-B32","first-page":"ljae360","article-title":"P60 Safe application of guselkumab in a psoriasis patient combined with coronary heart disease after percutaneous coronary intervention for acute myocardial infarction","volume":"191","author":"Lu","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025082212470808200_llaf172-B33","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/09546634.2021.1886231","article-title":"Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single-center real-life population","volume":"33","author":"Valenti","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025082212470808200_llaf172-B34","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016","edition":"8th edn"},{"key":"2025082212470808200_llaf172-B35","volume-title":"International Classification of Diseases for Oncology (ICD-O)","author":"World Health Organization","year":"2013"},{"key":"2025082212470808200_llaf172-B36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/jcm9010202","article-title":"Isolated anti-HBc: significance and management","volume":"9","author":"Moretto","year":"2020","journal-title":"J Clin Med"},{"key":"2025082212470808200_llaf172-B37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2025082212470808200_llaf172-B38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025082212470808200_llaf172-B39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.15585\/mmwr.mm6911a2","article-title":"Global epidemiology of tuberculosis and progress toward meeting global targets \u2013 worldwide, 2018","volume":"69","author":"MacNeil","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025082212470808200_llaf172-B40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.20287","article-title":"Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: recommendations from a SPIN-FRT expert consensus","volume":"39","author":"Torres","year":"2025","journal-title":"Acad Dermatol Venereol"},{"key":"2025082212470808200_llaf172-B41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis \u2013 time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J Eur Acad Dermatol Venerereol"},{"key":"2025082212470808200_llaf172-B42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14740338.2020.1736034","article-title":"A drug safety evaluation of risankizumab for psoriasis","volume":"19","author":"Huang","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025082212470808200_llaf172-B43","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/jdv.19406","article-title":"No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: multicenter case series of 35 patients","volume":"38","author":"Manzanares","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082212470808200_llaf172-B44","doi-asserted-by":"crossref","first-page":"106226","DOI":"10.1016\/j.jinf.2024.106226","article-title":"Risk for latent tuberculosis infection reactivation among patients with psoriasis on biologics treatment: a meta-analysis","volume":"89","author":"Zhu","year":"2024","journal-title":"J Infect"},{"key":"2025082212470808200_llaf172-B45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/108729100317696","article-title":"HIV-associated psoriasis","volume":"14","author":"Mallon","year":"2000","journal-title":"AIDS Patient Care STDS"},{"key":"2025082212470808200_llaf172-B46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/09564624231199510","article-title":"Effectiveness and safety of risankizumab in HIV patients with psoriasis: a case series","volume":"35","author":"Orsini","year":"2024","journal-title":"Int J STD AIDS"},{"key":"2025082212470808200_llaf172-B47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00403-024-03395-1","article-title":"Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024","volume":"317","author":"Shimon","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2025082212470808200_llaf172-B48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.25259\/IJDVL_790_2024","article-title":"Guselkumab for psoriasis management in an HIV positive patient","volume":"91","author":"Qiu","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2025082212470808200_llaf172-B49","doi-asserted-by":"crossref","first-page":"13030\/qt3db748cg","DOI":"10.5070\/D32411041999","article-title":"Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review","volume":"24","author":"Bartos","year":"2018","journal-title":"Dermatol Online J"},{"key":"2025082212470808200_llaf172-B50","author":"National Cancer Institute"},{"key":"2025082212470808200_llaf172-B51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14712598.2025.2471093","article-title":"Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"25","author":"Bruni","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"2025082212470808200_llaf172-B52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025082212470808200_llaf172-B53","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of \u00adpsoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025082212470808200_llaf172-B54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jdin.2024.02.019","article-title":"Real-world outcomes in patients with malignancy and moderate-to-severe \u00adpsoriasis treated with guselkumab","volume":"16","author":"Caza\u00f1a","year":"2024","journal-title":"JAAD International"},{"key":"2025082212470808200_llaf172-B55","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025082212470808200_llaf172-B56","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/jdv.19603","article-title":"Biologics in psoriatic patients with malignancies: where are we now? An Italian \u00admulticentric study","volume":"38","author":"Magnano","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf172\/62941040\/llaf172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1786\/62941040\/llaf172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/9\/1786\/62941040\/llaf172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:47:19Z","timestamp":1755881239000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/9\/1786\/8114730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf172","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,16]]}}}